Boston Scientific announces participation in the J.P. Morgan Healthcare Conference and conference call discussing fourth quarter and full year 2025 results
BSXMARLBOROUGH, Mass., Jan. 2, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13th, 2026, in San Francisco. Mike Mahoney, chairman and chief executive officer, Jon Monson, executive vice...
Boston Scientific announces 2025 Investor Day meeting and conference call discussing third quarter 2025 results
BSX(NYSE:BSX) MARLBOROUGH, Mass., Sept. 2, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Tuesday, September 30, 2025, beginning at 8:30 a.m. ET. The Investor Day meeting...
CMCT Announces 30,821-Square-Foot Lease to Boston Scientific Corporation at Penn Field, a 228,000-Square-Foot Creative Office Campus in Austin
BSXAUSTIN, Texas--(BUSINESS WIRE)--CMCT signs 30,821 sf lease with Boston Scientific at 228,000 sf Penn Field Creative Office Campus in Austin bringing property to 93% leased
$100 Invested In Boston Scientific 10 Years Ago Would Be Worth This Much Today
BSXIs Boston Scientific Gaining or Losing Market Support?
BSX$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
BSXP/E Ratio Insights for Boston Scientific
BSXBoston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook
BSXBoston Scientific ends global sales of ACURATE valves and halts FDA pursuit, citing rising regulatory burdens; expects to meet 2025 sales.
Needham Reiterates Buy on Boston Scientific, Maintains $115 Price Target
BSXCitigroup Maintains Buy on Boston Scientific, Raises Price Target to $125
BSX$1000 Invested In Boston Scientific 15 Years Ago Would Be Worth This Much Today
BSXForecasting The Future: 9 Analyst Projections For Boston Scientific
BSXMorgan Stanley Maintains Overweight on Boston Scientific, Raises Price Target to $125
BSX$100 Invested In Boston Scientific 15 Years Ago Would Be Worth This Much Today
BSXBarclays Maintains Overweight on Boston Scientific, Raises Price Target to $125
BSXBoston Scientific Says Second Phase Of ADVANTAGE AF Clinical Trial Of FARAPULSE Pulsed Field Ablation System Meets Primary Safety And Efficacy Endpoints
BSXNeedham Maintains Buy on Boston Scientific, Raises Price Target to $115
BSXBoston Scientific Analysts Boost Their Forecasts Following Upbeat Results
BSXRBC Capital Maintains Outperform on Boston Scientific, Raises Price Target to $120
BSXTruist Securities Maintains Buy on Boston Scientific, Raises Price Target to $117
BSXEvercore ISI Group Maintains Outperform on Boston Scientific, Raises Price Target to $112
BSXBaird Maintains Outperform on Boston Scientific, Raises Price Target to $120
BSXBoston Scientific Raises Annual Outlook After Strong Heart Devices Sales In Q1, Announces CFO Transition
BSXBoston Scientific topped Q1 revenue and EPS forecasts, lifted its 2025 outlook, and announced CFO Dan Brennan's retirement after nearly 30 years.
Boston Scientific Announced That Dan Brennan, Executive Vice President And Chief Financial Officer, Has Elected To Retire At The End Of June And Disclosed Jon Monson As His Replacement Effective June 30, 2025
BSXBoston Scientific Sees Q2 Adj EPS $0.71-$0.73 vs $0.71 Est and estimates net sales growth for the second quarter of 2025 to be in a range of approximately 17.5 to 19.5 percent on a reported basis versus the prior year period
BSXBoston Scientific Sees Q2 GAAP EPS $0.45-$0.47 vs $0.48 Est
BSXBoston Scientific Raises FY2025 Adj EPS Guidance from $2.80-$2.87 to $2.87-$2.94 vs $2.86 Est and estimate net sales growth for the full year 2025 to be approximately 15 to 17 percent versus the prior year period
BSXBoston Scientific Affirms FY2025 GAAP EPS Guidance of $1.86-$1.93 vs $1.96 Est
BSXBoston Scientific Q1 Adj. EPS $0.75 Beats $0.67 Estimate, Sales $4.66B Beat $4.57B Estimate
BSXEarnings Preview: Boston Scientific
BSXThis Boston Scientific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
BSXA Glimpse Into The Expert Outlook On Boston Scientific Through 13 Analysts
BSXNeedham Upgrades Boston Scientific to Buy, Announces $113 Price Target
BSXTruist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $113
BSXIs Boston Scientific Gaining or Losing Market Support?
BSXTrump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry
BSXTrump's 10% global tariff spares pharmaceuticals but impacts medical devices, with diabetes device makers facing the greatest strain. Large biopharma firms remain protected, while medtech companies navigate potential margin pressures and competitive shifts.
Price Over Earnings Overview: Boston Scientific
BSX$100 Invested In Boston Scientific 5 Years Ago Would Be Worth This Much Today
BSXGoldman Sachs Gains Confidence In Market Rebound, Upgrades GE Healthcare Amid China Recovery Hopes
BSXGoldman Sachs upgrades GE Healthcare to Buy, raising its price target to $100, as analysts see market stabilization and China sales recovering faster than expected.
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
BSXWatching Boston Scientific Corp; Hearing Investor Business Daily SwingTrader Buys Stock
BSXBeyond The Numbers: 17 Analysts Discuss Boston Scientific Stock
BSXBoston Scientific To Acquire SoniVie For $400 Million, Expanding Hypertension Treatment Portfolio
BSXBoston Scientific will acquire SoniVie for up to $600 million on 100% basis, adding the TIVUS ultrasound system to its hypertension treatment pipeline. Deal closes in H1 2025.
Needham Reiterates Hold on Boston Scientificto Hold
BSXBoston Scientific Agreed To Acquire SoniVie, A Privately Held Medical Device Company That Has Developed The Tivus Intravascular Ultrasound System For Approximately $360M And Up To $180M Upon Achievement Of A Regulatory Milestone
BSX$1000 Invested In Boston Scientific 10 Years Ago Would Be Worth This Much Today
BSXWhat Does the Market Think About Boston Scientific?
BSXReported Friday, Boston Scientific Prices €1.5B In Senior Notes, Consisting Of €850M 3.000% Due 2031 And €650M 3.250% Due 2034
BSX'Pacemaker Recall: Boston Scientific Corporation Recalls Accolade Pacemaker Devices Due to a Manufacturing Issue That May Lead to Early Device Replacement' - FDA
BSX$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
BSX